Further, several of the genes with increased expression in intra- compared to extracranial metastases predicted in at least 11 of 16 melanoma patients could potentially be of therapeutic relevance for the development of targeted treatment strategies for intracranial metastases (e.g. PPBP, HEPACAM, SLC24A2, SLC38A11, FMN2, PMP2). This evidence concerns the gene PMP2 and melanoma.